Rytvela lowers inflammation and improves newborn survival in preclinical study

New research suggests a potential breakthrough in the fight against preterm birth and its devastating consequences. A drug candidate, Rytvela, demonstrated a significant reduction in premature births and improved infant survival rates in a preclinical study using a mouse model. This outcome contrasts sharply with the current standard treatment, Nifedipine, which did not show similar benefits.

A New Approach to a Critical Challenge

Preterm birth, defined as birth before 37 weeks of gestation, is a leading cause of death in newborns. It affects 13.5 million births globally each year and results in over 900,000 deaths annually. Even for infants who survive, preterm birth can lead to short- and long-term health complications due to underdeveloped organs and exposure to inflammation.

Did You Know? Rytvela targets a pro-inflammatory signal called IL-1ß, but unlike other drugs that target IL-1ß, it avoids suppressing the immune system.

The study, published in The Journal of Immunology, compared Rytvela to Nifedipine, the most commonly used drug for preterm labor in North America. Rytvela decreased rates of preterm birth by 40%, effectively prolonging gestation and allowing for greater fetal development. Importantly, the drug also prevented inflammation-induced tissue injury in newborns, even when administered after the onset of inflammation.

How Rytvela Works

Inflammation in the uterus and placenta is a key driver of preterm labor, triggering a cascade of inflammatory signals that initiate labor. Rytvela works by targeting and decreasing the action of the IL-1ß signal, a major contributor to this inflammation. According to Dr. Tiffany Habelrih, lead author of the study, the intention behind Rytvela’s development was to “allow greater maturation of the fetus before birth while suppressing damaging inflammation,” something current treatments do not achieve.

Existing treatments for preterm labor primarily focus on attempting to stop or slow contractions. However, these methods typically only delay labor for less than 48 hours, offering limited opportunity to prevent preterm birth or improve fetal development.

Expert Insight: The current standard of care offers limited benefits in terms of preventing preterm birth and allowing for fetal development. Rytvela’s potential to address both of these critical areas represents a significant shift in the approach to managing preterm labor.

Dr. Sylvain Chemtob, senior author of the study, stated, “It’s rare for an innovation to combine so much scientific, clinical, and human potential.” He further emphasized that developing new drugs to stop preterm labor is “a decisive step for the health of newborns and their families around the world.”

What’s Next?

The researchers are currently finalizing their preclinical research and preparing for clinical trials involving human subjects. If these trials are successful, Rytvela could offer a new and more effective treatment option for women at risk of preterm birth. This drug could significantly reduce the number of preterm births and improve outcomes for both mothers and babies. However, further research is needed to confirm these promising results.

Frequently Asked Questions

What is the current standard treatment for preterm labor?

The current standard treatment for preterm labor in North America is Nifedipine, a drug that attempts to stop or slow contractions.

How does Rytvela differ from existing treatments?

Rytvela targets inflammation, a major contributor to preterm labor, and aims to prolong gestation and allow for fetal development. Current treatments primarily focus on delaying labor for a short period.

What stage of development is Rytvela in?

Rytvela is currently in the preclinical stage, with researchers finalizing their research and preparing to proceed to clinical trials in people.

Could a new approach to managing inflammation during pregnancy ultimately lead to healthier outcomes for both mothers and newborns?